Bristol-Myers Squibb Company (BMY)
| Market Cap | 96.96B |
| Revenue (ttm) | 45.01B |
| Net Income (ttm) | 8.03B |
| Shares Out | 2.03B |
| EPS (ttm) | 3.86 |
| PE Ratio | 12.39 |
| Forward PE | 7.00 |
| Dividend | $2.40 (5.02%) |
| Ex-Dividend Date | Apr 4, 2024 |
| Volume | 9,948,796 |
| Open | 48.44 |
| Previous Close | 48.26 |
| Day's Range | 47.70 - 48.55 |
| 52-Week Range | 47.58 - 70.94 |
| Beta | 0.39 |
| Analysts | Hold |
| Price Target | 60.75 (+26.99%) |
| Earnings Date | Apr 25, 2024 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $60.75, which is an increase of 26.99% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY). Such investors ar...
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AACR--KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with.
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain...
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT4--BMS Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia.
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT--Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT.
U.S. FDA allows expanded use of Bristol Myers' cell therapy
The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer.
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #CART--U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma.
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.
European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
PRINCETON N.J.--(BUSINESS WIRE)---- $BMY #COMMANDS--European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent.
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESG--Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company's meaningful progress...
MAI Capital's Grisanti offers 3 buys and a bail: Bristol Myers Squibb, Verizon, Hershey & Boeing
Chris Grisanti, MAI Capital Management chief equity strategist, joins 'The Exchange' to discuss how to trade Bristol Myers Squibb, Verizon, Hershey, and Boeing.
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progressio...
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study
Bristol Myers Squibb said on Thursday its experimental drug to treat Crohn's disease, a chronic inflammatory bowel condition, failed to meet the main goal in a late-stage study.
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #KRAZATI--Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint.
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Crohns--BMS Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia in Patients with Moderately to Severely Active Crohn's Disease.
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #bloodcancer--Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes.
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024.
Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
PRINCETON N.J.--(BUSINESS WIRE)---- $BMY #Abecma--BMS' Abecma Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory.
Bristol Myers liver cancer treatment meets main goal of late-stage study
Bristol Myers Squibb said on Wednesday a combination of its drugs, Opdivo and Yervoy, met the main goal of a late-stage study evaluating it as a first-line treatment for a type of liver cancer.
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces CheckMate -9DW Trial Evaluating Opdivo Plus Yervoy Meets Primary Endpoint of Overall Survival for the First-Line Treatment.
Bristol-Myers Squibb Company (BMY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bristol-Myers Squibb Company ("Bristol-Myers Squibb Company") (NYSE:BMY) conc...
BMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Bristol-Myers Squibb Company Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bristol-Myers Squibb Company ("Bristol-Myers Squibb Company") (NYSE:BMY) conc...
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign.
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded...
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's co...